Drug-Resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Zumla, Alimuddin ^a   Abubakar, Ibrahim ^b   Raviglione, Mario ^c   Hoelscher, Michael ^d   Ditiu, Lucica ^e   McHugh, Timothy D ^a   Squire, S Bertel ^f   Cox, Helen ^g   Ford, Nathan ^g,k   McNerney, Ruth ^h   Marais, Ben ⁱ   Grobusch, Martin ^j   Lawn, Stephen D ^h,k   Migliori, Giovanni Battista ^l   Mwaba, Peter ^m,v   O'Grady, Justin ^a   Pletschette, Michel ⁿ   Ramsay, Andrew ^c   Chakaya, Jeremiah ^o   Schito, Marco ^p   Swaminathan, Soumya ^q   Memish, Ziad ^r   Maeurer, Markus ^s   Atun, Rifat ^t,u   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

^e Stop TB Partnership   (Switzerland)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l IRCCS   (Italy)

^m MINISTRY OF HEALTH   (Zambia)

ⁿ EUROPEAN COMMISSION   (Belgium)

^o MINISTRY OF HEALTH   (Kenya)

^p NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^q NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^r ALFAISAL UNIVERSITY   (Saudi Arabia)

^s KAROLINSKA INSTITUTE   (Sweden)

^t TUBERCULOSIS AND MALARIA   (Switzerland)

^u IMPERIAL COLLEGE LONDON   (United Kingdom)

^v UNIVERSITY OF ZAMBIA   (Zambia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BCG VACCINE; BEDAQUILINE; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; DELAMANID; DNA VACCINE; ETHAMBUTOL; ETHIONAMIDE; GOLOTIMOD; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFAMPICIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL GENE; BCG VACCINATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG COST; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; GENOTYPING TECHNIQUE; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION PREVENTION; MICROBIOLOGICAL EXAMINATION; MOLECULAR PROBE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; PATIENT CARE; PATIENT MONITORING; PATIENT RIGHT; PEDIATRICS; PERIPHERAL NEUROPATHY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RPOB GENE; SCALE UP; SOCIAL ISOLATION; SPUTUM CYTODIAGNOSIS; TREATMENT OUTCOME; VESTIBULAR DISORDER; WORLD HEALTH ORGANIZATION;

ADULT; AFRICA; ANTITUBERCULAR AGENTS; CHILD; COMMUNICABLE DISEASE CONTROL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDEMIC DISEASES; HEALTH POLICY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PATIENT RIGHTS; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 84860368544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir858     Document Type: Article

References (72)

1. WHO. Tuberculosis: a global emergency. Geneva, Switzerland: World Health Organization, 1994.
2. WHO. Global tuberculosis programme: framework for effective tuberculosis control. Geneva, Switzerland: World Health Organization, 1994.
3. WHO. DOTS-Plus and the Green Light Committee. Geneva, Switzerland: World Health Organization, 2000.
4. WHO. Annual report 2008: Green Light Committee initiative of the working group on MDR-TB of the Stop TB Partnership. Geneva, Switzerland: World Health Organization, 2009.
5. WHO. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. Geneva, Switzerland: World Health Organization, 2011.
6. WHO. Multidrug and extensively drug-resistant tuberculosis (M/XDRTB): 2010 global report on surveillance and response. Geneva, Switzerland: World Health Organization, 2010.
7. Kemp JR, Mann G, Simwaka BN, Salaniponi FM, Squire SB. Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ 2007; 85:580-5.
8. Liu X, Thomson R, Gong Y, et al. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. Trop Med Int Health 2007; 12: 1464-71.
9. Long Q, Li Y, Wang Y, et al. Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res 2008; 8:202.
10. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
11. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13:1320-30.
12. van Ingen J, de Lange WC, Boeree MJ, et al. XDR tuberculosis. Lancet Infect Dis 2011; 11:585.
13. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997; 1(suppl 24):S121-30.
14. Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis 2008; 8:10.
15. WHO. Global tuberculosis control 2011. Geneva, Switzerland: World Health Organization, 2011.
16. Rieder HL, Lauritsen JM, Naranbat N, Katamba A, Laticevschi D, Mabaera B. Quantitative differences in sputum smear microscopy results for acid-fast bacilli by age and sex in four countries. Int J Tuberc Lung Dis 2009; 13:1393-8.
17. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:688-98.
18. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496-514.
19. WHO. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva, Switzerland: World Health Organization, 2008.
20. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-2.
21. WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "how-to"; practical considerations. Geneva, Switzerland: World Health Organization, 2011.
22. Lawn S, Nicol M. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-82.
23. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
24. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
25. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
26. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15:603-22.
27. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011; 184:269-76.
28. WHO. Global tuberculosis control. Geneva, Switzerland: World Health Organization; 2010.
29. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10:1117-21.
30. MSF. An evaluation of drug-resistant TB treatment scale-up. Geneva, Switzerland: Médecins Sans Frontières, 2011.
31. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4:e6914.
32. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-61.
33. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:684-92.
34. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14:413-9.
35. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009; 4:e7186.
36. Cox HS, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2:e1126.
37. Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182:426-32.
38. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
39. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4:e292.
40. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva, Switzerland: World Health Organization, 2011.
41. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen formultidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8:560-7.
42. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-405.
43. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010; 70:2201-14.
44. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3:e466.
45. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008; 52:3568-72.
46. Cox H, Ford N, Keshavjee S, et al. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis 2011; 11:259-60.
47. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010; 14:663-4.
48. Global Alliance for TB Drug Development. TB Alliance 2009 annual report: accelerating the pace, New York, NY: Global Alliance for TB Drug Development, 2009.
49. Menzies D. Minimum number of drugs and duration for effective MDR-TB treatment: individual patient meta-analysis. 41st IUATLD World Conference on Lung Health. Berlin, Germany, 2010.
50. CIBMTR. Sharing knowledge, sharing hope: Centre for International Blood and Marrow Transplant Research. Centre for International Blood and Marrow Transplant Research. 2011. http://www.cibmtr.org/About/Impact/Pages/index.aspx.
51. Bosne-David S, Barros V, Verde SC, Portugal C, David HL. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 2000; 46:391-5.
52. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997; 41:2035-6.
53. Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr Med Chem 2008; 15:809-25.
54. Friedland JS. Tackling tissue destruction in tuberculosis. Trans R Soc Trop Med Hyg 2008; 102:953-4.
55. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007; 51:2830-6.
56. IUATLD. STREAM to test a 9-month MDR-TB treatment regimen (in press). 2011. http://www.theunion.org/index.php/en/what-we-do/research/clinical-trials/ item/254-stream-to-test-a-9-month-mdr-tbtreatment-regimen. Accessed 5 July 2011.
57. WHO. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. Geneva, Switzerland: World Health Organization, 2007.
58. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africadan upward trend. Am J Public Health 2009; 99:1486-90.
59. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944-6.
60. Schaaf HS, Moll AP, Dheda K. Multidrug-and extensively drugresistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin Chest Med 2009; 30:667-83; vii-viii.
61. Cobelens FG. Tuberculosis risks for health care workers in Africa. Clin Infect Dis 2007; 44:324-6.
62. WHO. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva, Switzerland: World Health Organization, 2009.
63. Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am 2010; 24:727-49.
64. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011; 30:501-5.
65. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011; 12:31-8.
66. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis 2007; 7:140.
67. Schaaf HS, Willemse M, Donald PR. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2009; 28:748-50.
68. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009; 89:199-202.
69. Schaaf HS, Victor TC, Engelke E, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007; 26:203-5.
70. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross-and coresistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13:1355-9.
71. Torres-Russotto D, Landau WM, Harding GW, Bohne BA, Sun K, Sinatra PM. Calibrated finger rub auditory screening test (CALFRAST). Neurology 2009; 72:1595-600.
72. Marais BJ, Rabie H, Cotton MF. TB and HIV in childrendadvances in prevention and management. Paediatr Respir Rev 2011; 12:39-45.